SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending due to its selection by the U.S. Department of Commerce to distribute economic data on-chain, a move seen as a major step for decentralized infrastructure. The community is actively discussing potential price targets and the broader implications of government adoption of blockchain technology. Some users also believe that this could be the start of a long term hold.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

$DOG.X, a memecoin on the Bitcoin network, is trending as the community rallies around its fair distribution and potential to outperform other meme coins. Some believe it could become the leading meme on Bitcoin, citing its strong community and organic growth. The potential for listings on major exchanges and the backing of a publicly listed company, $CBLO, are also fueling interest.

WorldFinancial

WorldFinancial ($WLFI.X) is trending as the community discusses its potential, governance, and links to prominent figures. Community members are weighing in on potential buybacks, token burns, and the possibility of mass adoption through real-world asset tokenization. Some traders are noting recent price volatility and debating whether it presents a buying opportunity or a sign of a pump and dump scheme.

Wrapped Centrifuge

Wrapped Centrifuge is gaining attention as community members actively discuss its potential breakout and encourage others to take a look. Some users point to news and increasing volume as potential catalysts, while others highlight its low supply. There's also discussion around the difference between $CFG.X and $WCFG.X.

ProShares Trust - ProShares Short Dow30 -1x Shares

ProShares Short Dow30

$DOG is trending as the community discusses its potential as the 'DOGE of Bitcoin' and its fair, presale-free distribution. Bullish sentiment surrounds CBLO's increasing treasury holdings of DOG coins, with some anticipating ETF possibilities and tier 1 exchange listings. Conversation highlights $DOG's strong community and its activities within the Bitcoin ecosystem, particularly regarding Runestones and Ordinals.

StickyFam

StickyFam ($FAM.X) is trending as the community rallies around its potential, highlighting its growing follower base and recent listing on BingX. Comparisons to coins within the $DOGE.X and $SOL.X ecosystem are circulating, with many believing that $FAM.X is still early and poised for significant growth due to upcoming catalysts like CEX listings.

Gyrodyne LLC engages in the management of a portfolio of medical office and industrial properties. Its properties include Flowerfield, Port Jefferson Professional Park, Courtland Medical Center, and Grove. The company was founded by Peter James Papadakos in 1946 and is headquartered in St. James, NY.

Gyrodyne LLC

GYRO is trending due to news of a major land sale, which the company projects will significantly boost its net asset value. The community is discussing the stock's low float and potential for a substantial breakout, drawing comparisons to other recent low-float runners. Some traders are closely watching key breakout levels, anticipating a rapid move upwards if these levels are breached.

Dynamix Corp. is a blank check company, which engages for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on June 13, 2024 and is headquartered in Houston, TX.

Dynamix Corp - Ordinary Shares - Class A

The ticker change from DYNX to ETHM is driving interest, as the company moves closer to its merger with The Ether Machine. Community members are actively discussing the company's Ethereum holdings relative to its market cap and comparing it to other ETH-related stocks. Some are also speculating on the potential impact of new ETH acquisitions on the share price.

Alcoa Corp. engages in the bauxite mining, alumina refining, and aluminum smelting and casting. It operates through the Alumina and Aluminum segments. The Alumina segment consists of a refining system, including the mining of bauxite, which is then refined into alumina, a compound of aluminum and oxygen that is the raw material used by smelters to produce aluminum metal. The Aluminum segment is composed of smelting and casthouse system. The company was founded by Charles Martin Hall on July 9, 1886 and is headquartered in Pittsburgh, PA.

Alcoa Corp

Alcoa ($AA) is trending as the community discusses its strong earnings report and potential benefits from tariffs, though some caution about potential headwinds. Bullish sentiment is fueled by analyst upgrades and a positive long-term outlook, while others are wary of short-term volatility. Community members are actively trading options, anticipating price movements based on the latest news.

The Kraft Heinz Co. engages in the manufacture and market of food and beverage products. It operates through the North America and International geographical segments. The company was founded on July 2, 2015, and is headquartered in Pittsburgh, PA.

Kraft Heinz Co

Kraft Heinz is trending following an analyst upgrade and news of a potential company split, with community members discussing the implications of the split, including Warren Buffett's perspective and potential effects on shareholder value. The breakup aims to create leaner structures focused on different brand segments, but concerns remain about debt and overall value creation. Some investors are seeing it as a buying opportunity while others remain skeptical, particularly about the company's debt.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies

IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies IQVIA and Flagship Pioneering Announce Strategic Collaboration to...

Mineralys Therapeutics Inc. (195% increase in followers)Radnor, Pennsylvania-based Mineralys is a clinical-stage biopharmaceutical company developing treatments for hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA), and other conditions linked to dysregulated aldosterone.Its lead candidate, lorundrostat, is an orally administered, highly selective aldosterone synthase inhibitor designed for cardiorenal conditions.Last month, Mineralys reported positive topline results from its Phase 3 Launch-HTN and Phase 2 Advance-HTN trials evaluating lorundrostat for uncontrolled and resistant hypertension. Both studies met their primary efficacy endpoints with statistical significance.&nbsp;In February, Mineralys reported a smaller-than-expected quarterly loss and disclosed that cash, cash equivalents, and investments stood at $198.2 million as of Dec. 31, 2024, which it expects to support clinical studies and corporate operations through the first quarter of 2026.The stock has gained over 28% year-to-date, with short interest at 4.5%, according to Koyfin.Sana Biotechnology Inc. (177% increase in followers)Sana focuses on developing engineered cell therapies to repair or replace damaged or missing cells, as well as control and modify genes.This year, the company has attracted significant investor interest following a potential&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sana-biotech-stock-triples-after-type-1-diabetes-trial-data/chGBWsVRZO">breakthrough</a> in type 1 diabetes. In January, it demonstrated that its hypoimmune edits enabled islet cell transplants to survive without immunosuppression, a result that drew praise from analysts.Last month, Citizens JMP upgraded Sana's stock, citing the validation of its Hypoimmune platform in type 1 diabetes, upcoming SC291 data in autoimmune diseases expected in 2025, and a strong cash position of $152.5 million. The firm considers Sana undervalued.Jefferies notes that Sana has three assets in development across different disease areas and projects peak adjusted revenues of $2.8 billion.Sana's stock is up just over 3% year-to-date, with short interest at 17.7%, according to Koyfin.Aeon Biopharma Inc. (132% increase in followers)This is a clinical-stage biopharmaceutical company developing ABP-450, a botulinum toxin complex for treating neurological conditions. Evolus markets the same botulinum toxin complex cosmetically under the name Jeuveau.ABP-450 is already approved as a biosimilar in Mexico and India. Aeon holds exclusive development and distribution rights for therapeutic indications in the U.S., Canada, the EU, the U.K., and select international markets.The stock gained attention this year following a 1-for-72 reverse stock split in March to maintain NYSE American's minimum share price requirement.Last month, Aeon announced that CEO Marc Forth would step down on April 4 to pursue another opportunity, with Chairman Jost Fischer stepping in as interim CEO.Aeon's stock has plunged over 98% year-to-date, with short interest last at 1.7%, according to Koyfin.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

Mineralys, Sana, Aeon: These 3 Biotech Stocks Saw The Sharpest Retail Interest Spike In Q1

Three small-cap stocks have intrigued Stocktwits users the most among the biotech sector this year, thanks to promising data from clinical trials and a leadership shuffle.

Equity

Biotech stocks remain a hot sector for retail traders on Stocktwits,&nbsp;which collectively boast over 3.45 million followers.&nbsp;In January, several biotech names saw explosive gains as investors bet on breakthrough treatments, key partnerships, and regulatory milestones.According to Stocktwits data, these five biotech stocks saw the highest surge in retail following this month.CARGO Therapeutics Inc. (CRGX) – 445% Jump In FollowersCARGO Therapeutics, a clinical-stage biotech company focused on cancer treatments, saw its stock collapse even as retail interest surged.&nbsp;In January, the FDA cleared its Investigational New Drug (IND) application for CRG-023, a novel tri-specific CAR T therapy designed to tackle relapse factors in B-cell malignancies.&nbsp;However, the company later announced it would discontinue a Phase II trial of its lead candidate, firi-cel, after an ad hoc safety analysis revealed an unfavorable benefit-risk profile.&nbsp;Wall Street analysts issued downgrades, and CARGO’s stock is on track to plunge more than 76% in January — its worst month since going public in November 2023.&nbsp;Short interest stands at 15.1%, according to Koyfin data.Sana Biotechnology Inc. (SANA) – 185% Jump In FollowersSana Biotechnology, which focuses on engineered cell therapies, captured investor attention with a potential&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sana-biotech-stock-triples-after-type-1-diabetes-trial-data/chGBWsVRZO">breakthrough</a> in type 1 diabetes.&nbsp;The company demonstrated earlier this month that its hypoimmune edits allowed islet cell transplant survival without immunosuppression.&nbsp;Analysts praised the findings, driving the stock up roughly 114% in January — its best month since its March 2021 market debut.&nbsp;Short interest is at 16.6%.Silexion Therapeutics Corp. (SLXN) – 92% Jump In FollowersSilexion, an oncology-focused biotech developing RNA interference therapies, gained momentum after releasing preclinical data on a second-generation siRNA candidate, SIL-204.&nbsp;The treatment&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/slxn-stock-hits-record-low-after-pricing-5m-offering/chGtwKoRng">showed</a> synergistic efficacy when combined with first-line chemotherapy for pancreatic cancer.&nbsp;Although the stock gained just 2% in January, it marked its best month since November.&nbsp;Short interest remains low at 2.4%.AEON Biopharma Inc. (AEON) – 81% Jump In FollowersAEON Biopharma is developing ABP-450, a botulinum toxin complex similar to Evolus’ Jeuveau, for medical indications such as chronic migraine.&nbsp;Retail traders appeared to buy the dip after AEON priced a $20 million public offering earlier this month, which initially sent shares tumbling.&nbsp;The stock is headed for a 77% drop in January, its worst month since going public via a SPAC merger in July 2023.&nbsp;Short interest is just 0.2%, according to Koyfin.Kairos Pharma (KAPA) – 78% Jump In FollowersKairos Pharma, a clinical-stage biopharmaceutical company, saw retail interest soar this month after breaking key resistance levels and securing crucial investments.&nbsp;The company is testing its lead candidate, ENV105 — which targets a protein linked to resistance in cancer treatments — in Phase 2 trials for castrate-resistant prostate cancer and Phase 1 trials for lung cancer.The stock gained momentum following CEO John Yu’s positive comments at an investor healthcare summit this month and the completion of a $3.5 million PIPE transaction.&nbsp;Kairos shares are set to decline 2.6% in January, marking their worst month since October.&nbsp;Short interest remains&nbsp;negligible at 0.1%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail Traders Flocked To These 5 Biotech Stocks In January — Here’s Why

Biotech remains a high-risk, high-reward sector, and this month’s top draws reflect retail’s appetite for stocks with major clinical and regulatory catalysts.

This Biotech Penny Stock Is Up 120% This Year. Analysts Think It Can Still Triple From Here in 2025.

With positive results from a clinical trial targeting Type 1 diabetes, Wall Street is feeling hot on this little biotech stock.

Sana Biotechnology Inc.'s stock soared over 200% on Wednesday, on track to mark its best day on record, amid trading volumes spiking to 54 times the daily average.&nbsp;The surge followed highly positive analyst reactions to initial data from a groundbreaking type 1 diabetes trial using Sana's experimental cell therapy.The results, unveiled late Tuesday, came from a first-in-human, investigator-led study conducted in collaboration with Uppsala University Hospital.&nbsp;The trial evaluated UP421, an allogeneic primary islet cell therapy engineered with Sana's hypoimmune technology. Notably, the patient did not require immunosuppression for the therapy.&nbsp;Four weeks after transplantation, the study showed the survival and function of transplanted pancreatic beta cells, evidenced by circulating C-peptide levels, which indicate insulin production.&nbsp;Additionally, a mixed meal tolerance test confirmed insulin secretion in response to food, while MRI scans indicated sustained cell graft survival. Importantly, no safety concerns were identified, and the hypoimmune islet cells successfully evaded immune responses.Analysts were quick to praise the results, calling them a potential breakthrough.&nbsp;TD Cowen upgraded Sana to 'Buy' from 'Hold,' citing the proof of concept for hypoimmune technology's immune evasion properties, which it believes de-risks future applications for type 1 diabetes and beyond.&nbsp;Citi referred to the data as a "major scientific advance" for type 1 diabetes patients, highlighting the potential for broader applications in the allogeneic field. The brokerage maintained a 'Buy' rating with a $15 price target.&nbsp;H.C. Wainwright raised its price target for Sana to $11 from $8, increasing the probability of success for its hypoimmune programs and calling the trial results the "best case scenario" for the initial type 1 diabetes update.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SANA_sentiment_and_message_volume_Jan_8_96ba6e683f.png" alt="SANA sentiment and message volume Jan 8.png" width="1318" height="324"><figcaption>SANA sentiment and message volume Jan 8 as of 11:45 am ET | source: Stocktwits</figcaption></figure>On Stocktwits, sentiment for Sana turned 'extremely bullish' (96/100), with the stock climbing into the platform's top five trending symbols.&nbsp;<stembedurl>https://stocktwits.com/RingoZingo/message/599332380</stembedurl><stembedurl>https://stocktwits.com/StonksPacific/message/599334566</stembedurl>Despite the recent surge, Sana's stock remains over 80% below its February 2021 all-time intraday high, although it has gained more than 8% over the past year.&nbsp;Analysts now largely believe the latest data significantly changes the company's risk profile, potentially fueling further appreciation of its stock.For updates and corrections, email newsroom[at]stocktwits[dot]com.

An Asian teenager with type 1 diabetes uses an at home glucometer to test his blood sugar levels. | Image source: Getty Images

Sana Biotech Stock Triples After Type 1 Diabetes Trial Wows Analysts: Retail Erupts In Excitement 

Citi referred to the data as a "major scientific advance" for type 1 diabetes patients, highlighting the potential for broader applications in the allogeneic field.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...

Futures Slump As Yields, Dollar Soar

Futures Slump As Yields, Dollar Soar

 US equity futures were already rolling over following yesterday's momentum-driven rout, when a the latest report out of CNN (a polar opposite to the...

S&P Futures Climb Ahead of U.S. ADP Jobs Report and FOMC Meeting Minutes

March S&P 500 E-Mini futures (ESH25) are trending up +0.31% this morning, partially rebounding from yesterday’s losses, while investors awaited the Federal Reserve’s December meeting minutes, comments from a Fed official, and a fresh batch of U.S. economic data.

Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. It focuses on identifying and developing potential product candidates, executing preclinical studies, and acquiring technology. The company was founded by Steven D. Harr, Noubar B. Afeyan, Robert Taylor Nelsen, and Hans Edgar Bishop on July 2018 and is headquartered in Seattle, WA.

SANA
Sana Biotechnology Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SANA News

SANA Sana Biotechnology Inc